Recent advances in the treatment of prostate cancer

Annals of Oncology

Volumn 10, Issue 8, 1999, Pages 891-898

  Kuyu, H ^a   Lee, W R ^a   Bare, R ^a   Hall, M C ^a   Torti, F M ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Brachytherapy; Chemotherapy; Hormonal therapy; Prostate cancer; Recent advances

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HYDROCORTISONE; IDARUBICIN; KETOCONAZOLE; LEUPRORELIN; MEGESTROL ACETATE; NARCOTIC ANALGESIC AGENT; NILUTAMIDE; PACLITAXEL; SURAMIN;

BLADDER DISEASE; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG WITHDRAWAL; HORMONAL THERAPY; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECTUM DISEASE; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032878732     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008385607847     Document Type: Review

References (67)

1. Rosen MA, Goldstone L, Lapin S et al. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331.
2. Lange PH, Narayan P. Understaging and undergrading of prostate cancer; argument for postoperative radiation as adjuvant therapy. Urology 1983; 21: 113.
3. Bigg SW, Kavoussi LR, Catalona WJ. Role of nerve sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 1990; 144: 1420.
4. Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1987; 138: 1407.
5. Jones EC. Resection margin status in radical retropubic prostatectomy specimens: Relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990; 144: 89.
6. Labrie F, Dupon A, Cusan L et al. Down staging of localized prostate cancer by neoadjuvant therapy with flutamide and lupon: The first controlled and randomized trial. Clin Invest Med 1993; 16: 499-509.
7. Soloway MS, Sharifi R, Wajsman Z et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2(T2bNXMO) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995; 154: 424-8.
8. Gleave ME, Goldenberg SL, Jones EC et al. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9.
9. 2 prostate cancer: Interim results of a prospective randomize trial. J Urol 1995; 154: 429.
10. Goldenberg SL, Klotz LH, Srigley J et al. and Canadian Urologic Oncology Group. J Urol 1996; 156: 873-7.
11. Vailancourt L, Ttu B, Fradet Y et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20: 86-91.
12. Aus G, Abrahamsson PA et al. Hormonal treatment before radical prostatectomy: A three-year follow-up. J Urol 1998; 159 (6): 2013-6.
13. Zagars GK et al. Adjuvant estrogen following radiation therapy for stage C carcinoma of the prostate: Long-term results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1988; 14: 1085-91.
14. Byar DP. The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973; 32: 1126-30.
15. Bolla M et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300.
16. Pilepich MV et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45 (4): 616-23.
17. Pilepich MV et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997; 15: 1013-21.
18. Leibel SA, Zelefsky MJ, G. Kutcher. The biologic basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 1994; 21: 580-92.
19. Perez CA et al. Cost benefit of emerging technology in localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 39: 875-87.
20. Soffen EM et al. Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: A reduction in acute morbidity. Int J Radiat Oncol Biol Phys 1992; 24: 485-91.
21. Lee WR et al. Lateral rectal shielding reduces late rectal morbidity following high-dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a signficant dose effect. Int J Radiat Oncol Biol Phys 1996; 35: 251-7.
22. Zelefsky MJ et al. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand? Semin Radiat Oncol 1998; 8: 107-14.
23. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at five years after external beam radiation. J Urol 1995; 154: 456-9.
24. Hanks GE et al. Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > 10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35: 861-8.
25. Shipley WU et al. Advanced prostate cancer: The results of a randomized comparative trial of high-dose irradiation boosting with conformal protons compared with conventional-dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 3-12.
26. Blasko JC et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin N Am 1996; 23: 633-50.
27. Ragde H, Blasko JC, Grimm PD. Brachytherapy for clinically localized prostate cancer. Results at seven- and eight-year follow-up. Semin Surg Oncol 1997; 13: 438-46.
28. Zelefsky MJ et al. Long-term results of retropubic permanent I-125 implant of the prostate for clinically localized prostate cancer. J Urol 1998; 158: 23-9.
29. Critz FA et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49: 322-31.
30. Prestidge BR et al. Posttreatment biopsy results following interstitial brachytherapy in early-stage prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 31-8.
31. D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
32. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostate cancer: Initial results of the Medical Research Council trial. Br J Urol 1997; 79; 235-46.
33. McLead DG et al. Combined androgen blockade: The gold standard for metastatic prostate cancer. Eur Urol 1997; 32 (Suppl 3): 70-7.
34. Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-29.
35. Eisenberger MA. A comparison of bilateral orchiectomy with or without flutamide in stage D2 prostate cancer. N Engl J Med 1998; 339: 1036-42.
36. Moinpour CM et al. Quality of life in advanced prostate cancer: Results of a randomized therapeutic trial. J Natl Cancer Inst 1998; 90: 1537-44.
37. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Lancet 1995; 346: 265-9.
38. Caubet JF et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997; 49: 71-8.
39. Horwich A et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 1998; 81: 96-9.
40. Strum SB et al. Intermittent hormone blockade: Optimal induction duration and predictive factors for prolonged time off hormone blockade. Proc ASCO 1998; 17.
41. Higano CS et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996; 48: 800-4.
42. Goldenburg SL et al. Intermittent androgen suppresion in the treatment of prostate cancer: A preliminary report. Urology 1995; 45: 839-45.
43. Klotz LH et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986; 58: 2546-50.
44. Brufsky A et al. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology 1997; 49: 913-20.
45. Oh W et al. Secondary hormonal responses after initial peripheral androgen ablation therapy with finasteride and flutamide in advanced prostate cancer. Proc ASCO 1998; 17.
46. Boccardo F et al. Bicalutamide monotherapy versus flutamide plus gosrelin in prostate cancer patients. Preliminary results of an Italian Prostate Cancer Group Study. Proc ASCO 1997; 16.
47. Tyrell CJ et al. Improvements in subjective response in patients with advanced prostate cancer treated with 'casodex' (bicalutamide) 150 mg mono-therapy compared with castration. Proc ASCO 1998; 17.
48. Pummer K et al. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32 (Suppl 3): 81-5.
49. Janknegt RA et al. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: A randomized, multi-center study of ochiectomy alone versus orchiectomy plus estramustine phosphate. Urology 1997; 49: 411-20.
50. Hussain M et al. Androgen deprivation + four courses of fixed-schedule suramin in D2 prostate cancer patients: A Southwest Oncology Group phase II study. Proc ASCO 1998; 17.
51. Dawson NA et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997; 15: 1470-7.
52. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm. J Clin Oncol 1997; 15: 382-8.
53. Huan SD, Gerridzen RG et al. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632-4.
54. Small EJ et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997; 157: 1204-7.
55. Small EJ et al. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortizone in patients with advanced prostate carcinoma. Cancer 1997; 80: 1755-9.
56. Iverson P et al. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPRCA study 9002. J Urol 1997; 157: 929-34.
57. Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156-63.
58. Schhmid HP et al. A phase II study of oral idarubicin as treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Cancer 1997; 79: 1703-9.
59. Dimopoulos MA et al. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. Urology 1997; 50: 754-8.
60. Pienta KJ et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 1997; 50: 401-7.
61. Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer Am J Clin Oncol 1997; 20; 383-6.
62. Hernes EH et al. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: A phase II study. Br J Cancer 1997; 76: 93-9.
63. Miglietta L et al. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: Preliminary results of a pilot phase II study. J Cancer Res Clin Oncol 1997; 123: 407-10.
64. Raghavan D et al. Evolving strategies of cytotoxic chemotherapy for advanced prostate cancer. Eur J Cancer 1997; 33: 566-74.
65. Pienta KJ, Smith DC. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 1997; 24 (Suppl 15): 72-7.
66. Ellerhorst JA et al. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin Cancer Res 1997; 3: 2371-6.
67. Small EJ et al. Superiority of suramin + hydrocortisone over placebo + hydrocortisone: Results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. Proc ASCO 1998; 17.